Tumor cells carrying mutations in BRCA1/2 genes exhibit impaired DNA repair due to deficiencies in homologous recombination repair.375,376 Exploiting this vulnerability, PARP inhibitors are utilized to disrupt DNA damage repair, leading to the buildup of excessive DNA damage and consequent elimination of tumor cells in BRCA1/2-deficient TNBC.377 Recent clinical trial data have demonstrated that PARP inhibitors (such as olaparib or talazoparib) improved PFS and enhanced quality of life in patients with BRCA-mutated breast cancer when compared to single-agent chemotherapy (Table 3).378,379. This evidence concerns the gene BRCA1 and breast cancer.